Navigation Links
Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
Date:6/10/2008

Company Also Completes FDA Submission for Removal of Clinical Hold

BERKELEY HEIGHTS, N.J., June 10 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notice of allowances for two major patents from the European Patent Office for its pipeline product, tesetaxel, a leading oral taxane. The patents relate to composition of matter for the tesetaxel drug substance and to processes for its synthesis. The Company plans to broadly secure validation of these patents throughout the major countries in Europe. The European patents complement existing patents that have already issued in the United States. Genta holds worldwide exclusive licenses to these patents.

In a related matter, the Company announced that it had submitted a "complete response" to the Food and Drug Administration (FDA) and had requested that the clinical hold that had been placed on tesetaxel be lifted in order to allow resumption of clinical trials. Among other items, the submission included requested toxicokinetic analyses and a proposal for a new clinical study. Initial action by FDA on this submission is expected in the second quarter of 2008.

About Tesetaxel

Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both prototype agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side- effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).

With administration as an oral capsule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables development
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
2. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
3. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
4. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
5. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
6. Dr. Elizabeth Brown Joins Argenta TEC
7. Syngenta To Build Major Global Biotech Research Center in Beijing, China
8. Genta Restructures Operations to Focus on Priority Initiatives
9. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
10. Auditors for Genta Incorporated Express Going Concern Qualification
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)HOUSTON, Dec. 3 JourneyLite of Houston, LLC announced today that it has updated its facility to offer patients a second surgical option, vertical sleeve gastrectomy , along with the LAP-BAND®
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5
...al Branding Strategy, ST. LOUIS, April 30 Sigma-...tegration of its Riedel-de Haen(R),Laboratory Reag... 2008,( http://www.sigma-aldrich.com/rebranding )....e with our products and,services," said Josef Zihl... for the Research Specialties and Research Essenti...
...s,Inc. (Nasdaq: CADX ), a biopharmaceutical compa...alizing proprietary product candidates principally...that the company,s,President and CEO Theodore Schr...w at the following investment conferences:, -- D...t the InterContinental Hotel in Boston on Tues...
...mpany (NYSE: BMY ) invites investors and the gene...eting with stockholders at 10 a.m. ET on Tuesday,M...rd items to be,transacted, senior executives will ... information on how to listen to the webcast, plea...l-Myers Squibb website at, http://www.bms.com/ir ....
Other Biology Technology:Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 2
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Children exposed to secondhand cigarette smoke have an increased risk of developing lung cancer in adulthood, even if they never smoked. , Results of this study are published in Cance
(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot
Breaking Biology News(10 mins):Grooving down the helix 2Grooving down the helix 3Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cigarette smoking increases colorectal cancer risk 2PDI Reports 2009 Second Quarter Financial Results 13399 1PDI Reports 2009 Second Quarter Financial Results 13399 2PDI Reports 2009 Second Quarter Financial Results 13399 3PDI Reports 2009 Second Quarter Financial Results 13399 4PDI Reports 2009 Second Quarter Financial Results 13399 5PDI Reports 2009 Second Quarter Financial Results 13399 6PDI Reports 2009 Second Quarter Financial Results 13399 7PDI Reports 2009 Second Quarter Financial Results 13399 8PDI Reports 2009 Second Quarter Financial Results 13399 9Orexigen 28R 29 Therapeutics to Speak at Canaccord Adams Global Growth Conference 13397 1ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12 13395 1
...st of its kind study examining the effects of meth...g appears to cause abnormal brain development in c..., 2009, online issue of Neurology , the medical j..."Methamphetamine use is an increasing problem amon...ing number of children with prenatal meth exposure...
... 2009 Immigrant women are less likely to use foli...na bifida, particularly those who recently immigra...y a St. Michael,s Hospital physician in collaborat...University of Toronto. The study is the first to p...cid use in Canada. , "Our study,s findings report...
... Cincinnati (UC) cancer cell biologists have ident...cer susceptibility and development. They say this ...position to develop lung cancer for people with a ...ther investigation, they believe the gene could be...it from earlier, more aggressive lung cancer scree...
Other Biology News:Prenatal meth exposure linked to abnormal brain development 2Immigrant women may be at higher risk of having a baby with a birth defect 2Researchers identify specific lung cancer susceptibility gene 2
...icant secondary structure are often very difficult...ittle or no product. Yield, specificity and consis...g agents in PCR amplification reactions. Polymer-A...ates., Polymer-Aide is designed for molecular bi...
MutaGEL Parodontitis from Alpco Diagnostics
... Enhancer (with betaine) substantially improves PC...specificity for amplification of many DNA template...the base-pair composition dependence of DNA meltin...s pauses of DNA polymerase, and reduces secondary ...
...strip holder is designed for use with any Costar f...ew product number, created to easily match Corning...please order under the old Sigma-Aldrich number (Z...ce. ID clarifier: "egg crate" strip holder Sterili...
Biology Products: